Parenteral Nanocarriers for mRNA and Gene Therapy: Emerging Trends and Future Perspectives: A Narrative Review - Premier Science Cas delivery vectors, Crispr, Lipid nanoparticles, Parenteral mrna delivery, Polymeric nanocarriers, Self-amplifying RNA.

doi.org/10.70389/PJS...

#nanocarriers #mRNA #genetherapy

Schematic representation of nanovaccine approaches for NSCLC management. (a) siRNA-based gene silencing within tumor cells. (b) TME remodeling via immune activation approach to enhance tumor destruction.

This review summarizes advances in #cancer #nanovaccines, highlighting #nanocarriers, and innovations such as #immunotherapeutic nanovaccines, STING agonist vaccines, and #nanogels, emphasizing their potential to reduce cancer recurrence.
Nanotechnology Reviews: doi.org/10.1515/ntre...

Amazing work by Clive Prestidge and his team on Lipid #Nanocarriers for Antimicrobial and Cancer Applications #DDA2025 #DrugDelivery #Nanomedicine

🔥What if the deadliest #BrainCancer could finally be outsmarted?💥🧠 New #Nanocarriers just crossed the #BBB barrier! 🚀@mdpiopenaccess.bsky.social #GBM
Read 👇
doi.org/10.3390/ijms...

Using the MiLi-FE method, this #STTT study developed AR@ENV—microglia-derived #Nanocarriers co-loaded with #Rapamycin & AR7—that promotes synchronized activation of #Macroautophagy & #CMA in #AlzheimersDisease therapy. #medsky

#OpenAccess: doi.org/10.1038/s413...

🚀Folate-tagged #Nanocarriers + #Ultrasound = dual chemo-sonodynamic punch!💥💊Safe, precise & deadly—to #Tumors, not you!😎 @mdpiopenaccess.bsky.social #Innovation
doi.org/10.3390/ijms...

🔥What if the deadliest #BrainCancer could finally be outsmarted?💥🧠 New #Nanocarriers just crossed the #BBB barrier! 🚀 @mdpiopenaccess.bsky.social #GBM
Read 👇
doi.org/10.3390/ijms...

The video 🎥 of the #BeilsteinTalk “Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, Ludwig-Maximilians-Universität Munich, is NOW available 🔓 in the video portal @TIB_AVPortal of the @tibhannover.
🔗 […]

[Original post on hessen.social]

Nanocarriers breach blood-brain barrier to deliver anti-inflammatory medicine Oregon State University researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, opening the door to potential new therapies for a range of conditions, inclu...

phys.org/news/2025-04... #Health #Nanocarriers

New review highlighting recent advancements in development of personalised treatments for #T1D by active targeting of pancreatic beta cells using #Nanocarriers
#DiabetesResearch #Endocrinology #MedSky

Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers - Diabetologia Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects. Targeted drug delivery using nanocarriers has demonstrated potential for overcoming these limitations. The critical bottleneck limiting the development of beta cell-targeted therapies is a lack of highly specific beta cell markers. This review provides an overview of the use of nanocarriers for cell-targeted delivery and the current state of the field of beta cell targeting. Technologies such as systematic evolution of ligands by exponential enrichment (SELEX) aptamer selection, phage display screening, and omics datasets from human samples are highlighted as tools to identify novel beta cell-specific targets that can be combined with nanocarriers for targeted delivery of therapeutics. Ultimately, beta cell-targeted therapies using nanocarriers present a unique opportunity to develop tailored treatments for each stage of type 1 diabetes with the goal of providing individuals with treatment options that prevent further progression or reverse the course of the disease. Graphical Abstract

Jillian Collins & Nikki L. Farnsworth highlight recent advancements in active targeting of pancreatic beta cells using #Nanocarriers to develop personalised treatments for each stage of #T1D. #DiabetesResearch
tinyurl.com/34tkccm2

Let's start with #IPCF webinars for 2025! The next one will take place on January 31st
Registration open at ipcfseminar.wordpress.com/registration/
#nanocarriers
#drugdelivery
#molecularmodeling

Starting TOMORROW, 📅 Nov. 14, 2024, at 🕒 2:30 PM CET: "Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, Ludwig-Maximilians-Universität Munich, on 📅 Nov. 14, 2024 🕒 2:30–3:30 PM CET.

Register for FREE 🔗 […]

[Original post on hessen.social]

Join the online #BeilsteinTalk "Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, Ludwig-Maximilians-Universität Munich, on 📅 Nov. 14, 2024 🕒 2:30–3:30 PM CET.

Participation is FREE! Just register: 🔗 […]

[Original post on hessen.social]

Save the date: 📅 Nov. 14, 2024 🕒 2:30–3:30 pm CET

Online #BeilsteinTalk “Computational approaches in improving spermine-based RNA #nanocarriers" with Olivia Merkel, Ludwig-Maximilians-Universität Munich.

Register for FREE! 🔗 […]

[Original post on hessen.social]

Mainz-based scientists decipher stealth effect of #nanocarriers evading clearance by the #immunesystem - http://www.uni-mainz.de/presse/20124_ENG_HTML.php #medicine